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Introduction
Head and neck squamous cell carcinoma (HNSCC) affects more than 500 000 patients worldwide each year [1] . Major risk factors are tobacco use and excessive alcohol consumption, which have a synergistic effect [2] . In a subset of HNSCCs, especially those arising in the oropharynx, infection with high-risk human papillomavirus (HR-HPV) has also been proven to be carcinogenic [3] . Over the past 25 years, a highly significant increase in the prevalence of HPV-positive oropharyngeal squamous cell carcinomas (OPSCCs) has been observed [4] [5] [6] [7] , and differences between patient groups emerged. In general, patients with HPV-positive OPSCCs tend to be more frequently male and of a relatively younger age than their HPV-negative counterparts [7] [8] [9] [10] . Moreover, they have a better overall performance and are less likely to be smokers or heavy alcohol consumers [11] [12] [13] [14] . Although HPV-positive OPSCCs are commonly diagnosed at an advanced stage with multiple cervical lymph node metastases [7] , they have a more favorable prognosis than HPV-negative OPSCCs [7, [14] [15] [16] [17] . This may be due to an increased sensitivity to radiotherapy and other favorable biological tumor characteristics, combined with a better overall performance of the patients [12, 15] . HPV status is therefore routinely analyzed in OPSCCs, usually by performing p16 immunostaining on tumor tissue. p16
Ink4a , a tumor suppressor protein that is overexpressed in HPV-driven carcinomas, is a well-known surrogate marker for HPV status. OPSCCs showing p16 overexpression are often considered to be HPV-positive, but p16 immunostaining yields false positive results in 5%-20% of cases [14, [18] [19] [20] [21] [22] [23] .
Giving this prognostic role, the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) have adopted p16 status in the eighth edition of the TNM classification of malignant tumors, which was released in January 2017 and implemented in January 2018. In this edition, OPSCCs with p16 overexpression are distinguished from p16-negative OPSCCs and are classified and staged differently.
The new classification for p16-positive OPSCCs is based on several validated models in single-and multicenter cohorts from the United States and Canada [24] [25] [26] , but has only been tested on two small patient cohorts across Europe [24] , where p16-positive OPSCCs are notably less prevalent [14] . The first aim of this study was therefore to evaluate TNM-8 on a Dutch cohort of p16-positive OPSCC patients with regard to 5-year overall survival (OS). Considering that 5%-20% of p16-positive OPSCCs may be false positive with respect to HPV status, we also determined the relevance of additional HPV DNA testing.
Patients and methods

Study design
This study was carried out on an extended retrospective cohort, described previously by Rietbergen et al. [14] , and included all distant disease-free OPSCC patients treated with curative intent at VU University Medical Center (VUmc) Amsterdam (period 2000-2015, N ¼ 840), and Erasmus Medical Center (EMC) Rotterdam (period [2000] [2001] [2002] [2003] [2004] [2005] [2006] , N ¼ 372). The patients were identified through the Dutch Cancer Registries and included histologically confirmed invasive squamous cell carcinoma of the oropharynx (ICD-10 codes C019, C051, C052, C090-C099 and C100-C109).
In total, 1204 out of 1212 (99.3%) tumor biopsies could be retrieved from the pathology archives for HPV testing. The remaining eight cases could not be acquired and were excluded from this study. Patient characteristics, information on smoking habits and alcohol consumption, as well as clinical outcomes were obtained from the patient files by MR and AvB and affirmed and updated by IN. Survival data were verified with the Municipal Personal Records Database. Comorbidity was classified according to the Adult Comorbidity Evaluation-27 (ACE-27) index calculator [27] . Approval for this retrospective study was obtained from the Institutional Review Board. Secondary use of tissue specimen adheres to the guideline "Human Tissue and Medical Research: Code of Conduct for Responsible Use" (https://www.federa.org/codes-conduct).
HPV testing
All pre-treatment biopsies were tested for HPV on formalin-fixed, paraffin-embedded (FFPE) tumor specimen according to the validated test algorithm [13] , consisting of p16 immunostaining followed by GP5þ/ 6þ DNA PCR on p16-positive carcinomas. p16 immunostaining was considered positive when 70% of the tumor tissue showed moderate to strong diffuse nuclear and cytoplasmic p16 immunoreactivity. When the DNA PCR was negative, HPV16 E7 primers were used to exclude L1 integrations. This led to three possible outcomes: p16-negative, p16-positive/ HPV DNA-positive and p16-positive/HPV DNA-negative OPSCCs.
End points
Clinical end points were 5-year OS and progression-free survival (PFS). OS was defined as the time between the date of histologically confirmed OPSCC diagnosis and the date of death from any cause. Patients lost to follow-up were censored at the respective date. PFS was defined as the time between the date of histologically confirmed OPSCC diagnosis and the date of radiologically or histologically confirmed disease progression. Disease progression was defined as having residual disease after treatment completion, or as development of either a locoregional recurrence (local recurrence of the tumor within 2 cm and within 3 years of diagnosis of the initial tumor, or regional recurrence of lymph node metastases in previously treated levels of the neck) or distant metastases. Patients who died and patients with second primary tumors were censored at the respective date.
Statistical methods
Differences in patient characteristics between p16-negative, p16-positive/ HPV DNA-positive and p16-positive/HPV DNA-negative cases were assessed using the Pearson chi-square test, Student's t-test or Fisher's exact test. OS and PFS were calculated with the Kaplan-Meier method, and compared with the log-rank test. Harrell's C index was used to establish the predictive prognostic power of TNM-7 and TNM-8. The demographic and clinical characteristics of the three subgroups are listed in Table 1 . No significant age difference was found between the groups (one-way ANOVA P ¼ 0.94). Patients RT, radiotherapy; CRT, chemoradiotherapy; SURG, surgery; ND, neck dissection; brachy, local brachytherapy of the tumor. Italicized ¼ P-value. Bold italicized ¼ statistically significant P-value (P < 0.05).
Results
Patient characteristics
with p16-negative OPSCCs differed significantly from patients with p16-positive/HPV DNA-positive OPSCCs with respect to gender (P ¼ 0.002), comorbidity, pack years, unit years, tumor location, clinical tumor and nodal stage and treatment (all P < 0.001). These differences were not observed between the p16-negative and p16-positive/HPV DNA-negative OPSCCs, with the exception of the number of pack years (P ¼ 0.012).
Since HPV-related and HPV-unrelated OPSCCs also have distinct morphologic features [28, 29] , we carried out a histopathologic subanalysis on randomly selected p16-negative (N ¼ 50) and p16-positive/HPV DNA-positive (N ¼ 50) OPSCCs and all p16-positive/HPV DNA-negative (N ¼ 48) OPSCCs (supplementary Table S1 , available at Annals of Oncology online). p16-negative OPSCCs were generally keratinizing and moderately differentiated, while p16-positive/HPV DNA-positive OPSCCs were more often nonkeratinizing and poorly differentiated. p16-positive/HPV DNA-negative showed more morphologic resemblance to p16-negative rather than to p16-positive/HPV DNA-positive OPSCCs.
Evaluation of the eighth TNM classification on p16-positive OPSCCs
To evaluate TNM-8 and compare its predictive prognostic power with TNM-7, we staged all our p16-positive OPSCCs according to both classifications.
When staged according to TNM-7, 13 patients (3.4%) had stage I disease, 28 (7.2%) stage II disease, 76 (20%) stage III disease, 237 (61%) stage IVA disease and 34 (8.8%) stage IVB disease. Five-year OS was 68% for stage I and II combined, 85% for stage III and 72% for stage IVA and IVB combined ( Figure 1A) . Although the differences in outcome between the groups were significant (stage I-II versus stage III: P ¼ 0.036; stage III versus stage IV: P ¼ 0.031), five-year OS was lower for stage I and II disease than for stage III and IV disease, demonstrating TNM-7 limitations.
When classified according to TNM-8, 220 patients (57%) had stage I disease, 100 (26%) stage II disease and 68 (18%) stage III disease. Five-year OS rates for stage I, II and III were 81%, 77% and 48%, respectively ( Figure 1B) . Survival curves varied significantly between stage II and III (P < 0.001), but not between stage I and II (P ¼ 0.32). Harrell's C index was 0.53 for TNM-7 and 0.63 for TNM-8.
The majority of p16-positive OPSCCs are located in the tonsils and base of the tongue. Moreover, in a previous study a prognostic advantage of p16-positivity in OPSCCs outside these subsites was not observed [30] . We therefore also applied TNM-8 on p16-positive OPSCCs solely from the tonsils and base of the tongue (supplementary Figure S1 , available at Annals of Oncology online). This did not improve the discrimination between stage I and II disease.
As mentioned previously, patients with TNM-7 disease stage I-II experienced a worse 5-year OS than those with stage III and IV disease. In addition, early stage OPSCCs also had a shorter PFS than stage III OPSCCs (supplementary Figure S2A , available at Annals of Oncology online, accompanied by 5-year PFS for TNM-8 in supplementary Figure S2B , available at Annals of Oncology online). Of these 41 patients with stage I and II disease, four patients (9.8%) experienced a locoregional recurrence.
Closer investigation of these cases demonstrated that two of the four OPSCCs were p16-positive, but HPV DNA-negative.
From our entire cohort of p16-positive OPSCCs, 48 out of 388 cases (12.4%) were HPV DNA-negative. Five-year OS of this subgroup was significantly worse than for p16-positive/HPV DNA-positive OPSCCs (P < 0.001), and more comparable to the survival curve of the p16-negative cases (Figure 2 ). Besides this difference in prognosis, p16-positive/HPV DNA-negative OPSCC patients also differed clinically and histopathologically from p16-positive/HPV DNA-positive OPSCC patients (Table 1 and  supplementary Table S1 , available at Annals of Oncology online). Based on the clinical differences, we developed an algorithm to predict which p16-positive OPSCCs are likely to be HPV DNA-positive (supplementary Table S2 , available at Annals of Oncology online). While not perfect, it does improve correct classification.
Although p16-positive/HPV DNA-negative OPSCCs were more often treated with radiation monotherapy rather than chemoradiation, survival curves for the two modalities did neither differ significantly within this subgroup (log rank P ¼ 0.998), nor in the total cohort of OPSCC patients (log rank P ¼ 0.359).
Considering that p16-positive/HPV DNA-negative OPSCCs do not have the same favorable prognosis as p16-positive/HPV DNA-positive OPSCCs, we also evaluated TNM-8 exclusively on the p16-positive/HPV DNA-positive OPSCCs (N ¼ 340). Fiveyear OS rates were 85%, 79% and 56% for stage I, II and III, respectively (Figure 3 ). Harrell's C index improved further to 0.64.
Discussion
This is the first study to evaluate TNM-8 on a Dutch cohort of p16-positive OPSCC patients from two university medical centers. The attributable fraction of p16-immunopositive OPSCCs in this study was 32.2%, which is significantly lower than in the United States and Canada, where attributable fractions up to 60%-70% are reported [24, 31] . Nonetheless, our study demonstrates that TNM-8 is superior to TNM-7 in classifying Dutch p16-positive OPSCC patients in prognostic subgroups, as indicated by the higher Harrell's C index.
Still, TNM-8 may be further refined in the future, especially for stage I and II disease. As can be observed in our current cohort, as well as in the study by O'Sullivan et al. and various other validation studies [24, 32, 33] , the survival curves for stage I and II disease are not yet separated optimally, with no significant difference in 5-year OS. We speculate that this may in part be explained by the fact that some p16-positive OPSCCs are HPV DNA-negative. As we know from previous research [14, [18] [19] [20] [21] and also found in our current study, 10%-20% of p16-positive OPSCCs are negative for HPV DNA. A former study by Rietbergen et al. demonstrated that patients with p16-positive, but HPV DNA-negative OPSCCs had a worse prognosis than patients with a truly HPV DNA-positive OPSCC, but the number of cases was small [14, 34] . Hence, we divided our extended cohort of p16-positive OPSCCs into a p16-positive/HPV DNA-positive and a p16-positive/HPV DNA-negative group and showed again that the latter group has a significantly less favorable prognosis and also distinct demographic, clinical and histopathologic characteristics compared with the p16-positive/HPV DNA-positive group. This observation in a larger cohort indicates that p16 overexpression does not equal an HPV-positive status.
When we evaluated TNM-8 on the truly HPV DNA-positive cohort, the differences in 5-year OS between stage I and stage II disease became more apparent (yet still not statistically significant), and the Harrell's C index improved slightly. Although this may have minor consequences for future tumor staging, we strongly believe that HPV DNA analysis in p16-positive OPSCCs should be carried out when considering treatment deintensification. In case circumstances do not allow additional HPV DNA testing, the clinical characteristics and histopathologic features described in the supplementary material may be used, but the prediction algorithm possibly requires adaptation to the local situation, and currently appears somewhat unlogical for a number of the weighing factors.
The limitation of this retrospective study is that, although we analyzed a non-selected cohort of over 1200 OPSCC patients, the number of p16-positive/HPV DNA-positive and p16-positive/ HPV DNA-negative cases was limited, due to the relatively low attributable fraction of p16-positive OPSCCs in the Netherlands. When we staged the 388 p16-positive OPSCCs according to TNM-7, stage I and II OPSCCs had a significantly lower 5-year OS than stage III and stage IV OPSCCs. This may be the consequence of the unequal distribution of patients over the different disease stages, with only 41 cases (10.6%) classified as stage I and II disease. Five-year PFS of early stage OPSCCs was 89.0% (supplementary Figure S2A , available at Annals of Oncology online), implying that part of the low OS could be explained by disease-unrelated causes.
In conclusion, we demonstrated that TNM-8 is superior to TNM-7 in dividing p16-positive OPSCCs into prognostic subgroups, also in a geographical region with a relatively low attributable fraction of HPV. However, one out of eight p16-positive OPSCCs was HPV DNA-negative. These cases had a significantly less favorable prognosis, indicating the importance to perform additional HPV DNA testing for predicting prognosis and when considering treatment de-intensification.
Funding
European Union in the frame of the H2020 Grant Agreement 689715 BD2Decide.
